Everything That Makes Truemed Valuable Is Borrowed

Most companies are misunderstood because people read their homepage. Truemed is misunderstood because people read its press.

And the press is unusually good — this is the trap — unusually accurate. A serial health-and-nutrition founder and a co-founder who now advises the Secretary of Health and Human Services set out to fix American healthcare from the wrong end — prevention instead of sick-care — and Andreessen Horowitz led a $34 million round to back them. Three thousand brands, two million shoppers, two straight years of tripling revenue, the marquee logos of the wellness economy behind it: Peloton, Oura, Nike, Garmin. The usual correction — don't believe the marketing — doesn't apply here. Every fact is real, and a16z's own framing for the company — redirecting the flow of American healthcare spending from managing illness to creating health — is a fair account of what it hopes to become. It is not an account of the business.

Because here is what the business is not. Truemed does not sell healthcare. It does not employ the doctors who write its letters. It does not decide whether a single claim gets reimbursed. It does not make any of the products it helps you buy. Take away everything it neither owns nor does, and what remains is the one question the press never asks: where does the money come from?

I. How the money actually works

The answer is a single document. Between a shopper who wants to spend pre-tax dollars on a product that wouldn't ordinarily qualify, and an IRS rule that reserves those dollars for medical expenses, sits a Letter of Medical Necessity: a clinician's note that reclassifies the purchase as medical. Truemed produces that note. It doesn't write the rule. It doesn't make the product. It doesn't reimburse the claim. It owns the one link in the chain where a purchase changes category.

Watch a single transaction. A customer reaches checkout on Oura's website and is offered the option to pay with HSA/FSA. She fills out a short health questionnaire — a few minutes, no in-person visit. A licensed clinician, employed by a separate medical group Truemed contracts with, reads her answers and issues the letter. Her ring is now a reimbursable medical expense; she pays with her benefits card, or pays normally and files for reimbursement. Oura books a sale. The force underneath is plain arithmetic: pre-tax dollars are worth roughly thirty percent more than post-tax ones, so the letter is worth about thirty percent of the price.

Who pays Truemed is the part the marketplace framing obscures. Not, in the main, the shopper — when she buys from a partner brand, the letter is free to her. The merchant carries the cost. And the merchant pays because the merchant is the one who gets paid: higher conversion, larger baskets, better retention among customers saving thirty percent. It is the merchant's return, not the shopper's fee, that Truemed's own materials advertise. What it charges for that return, it won't say — asked directly, its help center answers that pricing "depends on your integration type" and points you to the partnerships team. Its competitors are blunter: Flex publishes four percent per transaction; Sika prices on a percentage too. Truemed's cut sits behind a "contact us," in the same place theirs sit — a percentage of the spending its letters unlock. (One narrower stream runs the other way: for a standalone service like a gym membership bought outside the partner flow, the shopper does pay — about thirty dollars for the review, refunded if the claim can't be salvaged. The one case where the shopper is billed, and not the main event.)

So the business resolves to one sentence, and it isn't the sentence a marketplace would write. Truemed doesn't earn when you discover a product. It earns when a purchase you were already weighing gets reclassified as medical — a cut of spending it unlocks but never holds, on goods it doesn't make, cleared by a decision it doesn't control. It doesn't own the road. It owns the gate, and it charges for the crossing.

II. Why the gate collects

A tollgate earns only if two things hold: the crossing has to be legal enough that people will pay to make it, and no one with the power to tear the gate down can be bothered to. Both hold for Truemed right now. Neither is something it built.

Legality first. The letter works because the rule it leans on is genuinely open to it — the tax code lets pre-tax dollars pay for the "diagnosis, cure, mitigation, treatment, or prevention of disease," and a clinician's judgment that a mattress helps manage a diagnosed condition is the kind of call the rule was written to accept. That the call is made in two minutes, from a questionnaire, without an exam, doesn't make it plainly illegal. It makes it gray: defensible letter by letter, questionable in aggregate. The incentive built into the model runs toward issuing, not gating — a wider net is more unlocked spending — and each letter carries the specifics, a diagnosis, an ICD-10 code, a named product, that are what the only review that actually happens, the plan administrator's, checks for. Truemed's own help center concedes the soft spot: a letter that reads as general wellness rather than treatment for a specific condition is, in its words, "likely to be denied." Which leaves a question the model doesn't resolve — if letters clear for nearly everyone who asks, how much distinguishing work is "medical necessity" still doing? The compliance is real. Whether it is sufficient is a different question — and it is answered only if the pattern, rather than the individual letter, ever becomes the thing under scrutiny.

Which turns on the harder question — not whether the crossing is legal, but why nobody closes it. Here is the deepest fact about this business, and it is structural: there is no obvious institutional enforcer. When a shopper uses a letter to buy an Oura ring with pre-tax dollars, no insurer is defrauded, no patient is harmed, no federal program is billed. She spends her own money; the only party out anything is the U.S. Treasury, which collects slightly less tax. And the Treasury's tool is the weakest in American health regulation — it can audit the individual, years later, and disallow the deduction: civil, rare, and with the paperwork falling on the shopper, not on Truemed. Set that against the last companies to run this exact shape. When telehealth outfits mass-produced "medical necessity" documentation to unlock durable-medical-equipment purchases, the Justice Department charged them criminally and sent people to prison — because that documentation billed Medicare, and defrauding a federal payer is a felony with an agency behind it. Truemed's letters bill no one. The same shape that was a crime against Medicare is, against the FSA/HSA rulebook, merely an aggressive reading of a tax provision. The move didn't get safer. The payer changed — and the payer is what supplies the enforcer.

The other doors are shut for the same species of reason. A state medical board could discipline a doctor for signing letters without an exam, but the strict rules apply mainly to prescriptions, while a low-stakes documentation letter falls in the low-risk category telehealth regulation has grown permissive toward. The one live avenue is the Federal Trade Commission, which polices deceptive marketing and could someday move on a "save thirty percent" claim that oversells how many people qualify — which is why every player in the category, Truemed included, staples the same line to the promise: for qualified customers, savings vary. The exposure is real; the umbrella is already up.

But the enforcer worth watching was never a regulator. Every letter clears only if the party that actually pays out — the plan administrator, the WEX or Optum that adjudicates the reimbursement — accepts it, and that party needs no rule change and no enforcement action to stop accepting. It can tighten what it takes for this category of letter quietly, in a policy update, and the reimbursements stop clearing; the thirty percent evaporates, the merchant's return with it, Truemed's cut with that — in that channel, with no court, no headline, no warning. The regulators are the slow, civil, rare risk the category already keeps an umbrella against. The administrator is the fast, invisible one it can't paper over — and it is the same party that, if prevention spending ever went standard, would inherit the value outright.

And then the wind at its back, the part least under its control. The company was co-founded by a figure central to the movement now steering federal health policy — a Make America Healthy Again advisor to the Secretary of Health and Human Services — and that movement's central claim, that food and exercise are medicine, is the precise premise Truemed sells. It cannot bank the coincidence, and it knows it: the co-founder has divested his stake, and the company now takes pains to say health "shouldn't be a political topic." None of the conditions that make this business collect — the open rule, the missing enforcer, the political weather — belong to Truemed. It collects because the crossing is, for now, exactly as passable as it needs to be. It cannot make it stay that way.

III. The engine, and the bet on top of it

Go back to the road. The question is no longer whether Truemed collects — it does — but whether any part of that position becomes harder to copy, or harder to leave, over time. Take the pieces one at a time, because they answer different questions, and only one of them is the business the company talks about.

Is the machinery its own? No — and the proof is that other people have it too. The clinical review that issues the letter runs on telehealth infrastructure Truemed rents from a third-party vendor, staffed by clinicians it contracts from a separate medical group: it buys clinical capacity, it doesn't own it. The same rented plumbing is available to anyone who wants to stand up the identical flow, and several have — Flex, Sika, a Shopify-app newcomer, and a three-million-dollar startup called Burst among them — because the parts are for rent, not for building. Whatever Truemed's edge is, it is not the technology. The technology is a commodity, and the commodity is the entire operation minus the brand roster.

Is the roster locked? Only loosely. A brand that accepts Truemed can also accept Flex; a shopper who saves thirty percent through one saves it through another. Nothing in the arrangement stops a merchant from adding a second provider or moving to a cheaper one, and the price pressure competition brings is already on the board — the newer entrants undercut on rate, one dropping the percentage model for a flat monthly fee. Truemed leads on how many brands it has signed. That is a real lead, and a conventional one: further along in a land grab, not holding ground no one else can take.

Has the marketplace become its own thing? This is the part that matters, because it is the part that could turn a lead into a moat — and here the honest answer is not yet, and not clearly. Truemed is plainly trying: it runs a browsable marketplace, tells merchants that shoppers "discover" their brands through it, and reports incremental revenue from that discovery — the opening of a claim that the marketplace creates value on its own, apart from the tax mechanics underneath. The traffic doesn't yet carry the claim. By third-party traffic estimates, Truemed's own storefront draws on the order of a hundred and fifty thousand visits a month — smaller than the plain HSA-eligible stores it sits beside — with brief, shallow sessions, and it sends most buyers onward to the brand's own site to check out. The exact figure isn't the point, and the argument doesn't rest on it: the two million shoppers the company cites aren't arriving at that storefront at all; they meet Truemed as a payment option on someone else's page. Those are two different numbers — marketplace traffic and checkout reach — and the distinction is the whole question. And the primary observable reason any of them finishes the flow is the discount. A marketplace people come to in order to discover things is a different asset from a payment button people accept in order to save money, and on the evidence available Truemed is still far more the second than the first. The marketplace is the bet. The engine is still the letter.

And the letter is not a moat either — Section II already showed why: it clears only while the rule stays open and no enforcer arrives, conditions that belong to the environment, not the company. So neither piece is yet defensible: the engine is rented and rests on conditions it doesn't control; the marketplace that could stand on its own hasn't been shown to. Which is exactly why the marketplace matters more than its traffic suggests — it is the company's one attempt to build something that would still be worth owning if the conditions changed. Whether it succeeds is genuinely open. That it hasn't yet is what the outside evidence shows.

Then the structure turns once more, and this is the hardest thing to see. The tollgate's position depends on the letter being two things at once: necessary — without it the purchase doesn't qualify — and contestable — the gray of Section II. Remove either and the gate loses its place. A crackdown removes it from one side: tighten the rule and the letters stop clearing. A full legitimization removes it from the other — and that is the direction the company and its backers are pushing, toward a world where spending pre-tax dollars on prevention is normal, endorsed, built into the rails. Trace that world's structure, not its odds. If eligibility becomes standard, the letter stops being scarce. If the rails carry HSA/FSA acceptance natively, the parties positioned to keep the value are the ones who already hold the balances, the cards, and the float — the account administrators — not an intermediary that was charging to bridge a gap that has closed. The event that would most enlarge the prize is the same event that would most erode the toll. Crackdown and legitimization sit on one axis: both resolve the ambiguity, and the ambiguity is the position. The company's best case and its dissolution reach it through the same door — which is exactly why everything now turns on whether the marketplace becomes something more than the letter.

The numbers I can't get — the exact revenue, the margin — don't change any of this. A bigger version of this company is a bigger toll on the same crossing.

IV. What the public record can't settle

Two questions remain — not an interview, and not what a podcast asks. They are the points where the public evidence stops, and the answer would still change part of this reading.

On the bet. Is the marketplace already generating demand that would survive the LMN flow being switched off — customers who arrive to discover, and buy, for reasons the thirty-percent savings doesn't supply? The public evidence does not yet show otherwise. That answer marks the line between an intermediary and a destination, and it is the one that would rewrite Section III.

On the paradox. If spending pre-tax dollars on prevention became standard tomorrow — eligibility clarified, HSA/FSA acceptance built into the rails — where would Truemed still create value?